Bacterial Vaginosis. Diseases of the Genitourinary system
Conditions
Interventions
Intervention 1: The first intervention group, Oral tablet of Metronidazole 250 mg
2 tablet
every 12 h, is given for 7 days. Intervention 2: The second intervention group vaginal cream of Jaft (one Applicator every night) is given coccurent with oral tablet of Metronidazole 250mg, 2 table
Treatment - Drugs
The first intervention group, Oral tablet of Metronidazole 250 mg
every 12 h, is given for 7 days.
The second intervention group vaginal cream of Jaft (one Applicator every night) is given coccurent with oral tablet of Metronidazole 250mg, 2 tablets every 12 h.
Sponsors
Vice Chancellor for Research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Willingness to cooperate in the study; Married women of reproductive age (18 - 45); Symptoms of BV on clinical examination and confirmed by Amsel criteria (having three of four criteria) and confirmation by Gram stain and Nugent score should be 7-10; Lack of recent use of oral and topical medications such as Alkaloids, Anti-parasitic, Immunosuppressive drugs and other drugs during the past two weeks, according the patient report; No sexual intercourse during the past 24 hours; Lack of abnormal uterine bleeding (AUB); Lack of frequent bacterial infections which are resistant to treatment; Not to be pregnant and lactation; Lack of vaginal douche in the past 48 hours; Lack of specific diseases such as Liver disease, diseases of the Central Nervous System, Diabetes, Immune deficiency, according to patient report; Non-use of broad-spectrum Antibiotics, Anti-prostaglandins, Hormone therapy and Immunosuppressive, Anticoagulant and drug abuse in recent months; No history of hypersensitivity to Metronidazole; The patient should have only BV not other types of Vaginitis. Exclusion Criteria: Possible sensitivity to the drug (vaginal cream of Jaft), which is not seen so far; Lack of application of vaginal cream (Jaft or Placebo) and oral Metronidazole or discontinuing treatment; Taking any medication affecting the vaginal cream including Alkaloid drugs; Taking any medication affecting the symptoms of BV including broad-spectrum Antibiotic to treat other infections in the patient; Unwillingness of patients to continue or to cooperate; People who are considered sick on the patient's clinical symptoms but their test results does not endorse BV.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginal Discharge. Timepoint: Before and after the treatment of a week. Method of measurement: Through Smears of Vaginal discharges and Gram stained smears. | — |
Secondary
| Measure | Time frame |
|---|---|
| To reduce infectious factors such as bacteria and clinical symptoms. Timepoint: After a week of treatment. Method of measurement: Through the smears of vaginal discharges and gram stained slides. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZeinab Moshfeghy
School of Nursing and Midwifery, Shiraz University of Medical Sciences
Outcome results
None listed